



EnteroMedics to Present at the 28th Annual J.P. Morgan Healthcare Conference

ST. PAUL, Minn., Jan 05, 2010 (BUSINESS WIRE) -- EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity and other gastrointestinal disorders, announced today that Mark B. Knudson, Ph.D., Chief Executive Officer, is scheduled to present at the 28th Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 14th at 8:30 a.m. Pacific Time. Dr. Knudson will provide an overview of the Company and an update on its VBLOC^(R) vagal blocking therapy development program.

The presentation will be webcast live and may be accessed by visiting EnteroMedics' website at www.enteromedics.com. A replay of the webcast will also be available immediately after the conclusion of the presentation. Investors can access the webcast under "Press Room" in the "Investors" section of EnteroMedics' website.

About EnteroMedics Inc.

EnteroMedics is a development stage medical device company focused on the design and development of devices that use neuroblocking technology to treat obesity and other gastrointestinal disorders. EnteroMedics' proprietary neuroblocking technology, VBLOC(R) vagal blocking therapy, is designed to intermittently block the vagus nerves using high-frequency, low-energy, electrical impulses. EnteroMedics is currently conducting a feasibility study examining VBLOC Therapy's effects on blood glucose levels in diabetic patients outside of the United States. For more information, visit www.enteromedics.com.

Caution-Investigational device. Limited by U.S. Federal law to investigational use.

The implantation procedure and usage of the Maestro(R) System carry some risks, such as the risk generally associated with laparoscopic procedures and those related to treatment as described in the EMPOWER clinical trial informed consent.

SOURCE: EnteroMedics Inc.

EnteroMedics Inc.
Greg S. Lea, 651-789-2860
ir@enteromedics.com

Copyright Business Wire 2010